Bailard’s Lyell Immunopharma LYEL Stock Holding History

Bailard’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,205	Closed	-$187K	–	776
2021 Q4	$187K	Buy	+1,205	New	+$269K	0.01%	698

Other funds holding LYEL

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bailard's LYEL Position: Q1 2022 in Review

Bailard sold out of Lyell Immunopharma (LYEL) in Q1 2022, closing a stake of 1,205 shares — an estimated $187K sold.

Bailard first reported a position in LYEL in Q4 2021 and held it in 1 quarter. The position peaked at $187K in Q4 2021. 79 funds tracked by Wall St. Rank hold LYEL as of Q1 2022.

Bailard reported no remaining Lyell Immunopharma position as of Q1 2022 after selling out during the quarter.
Bailard sold 1,205 Lyell Immunopharma shares in Q1 2022, an estimated $187K.
Bailard first reported a position in Lyell Immunopharma in Q4 2021 and held it in 1 quarter.
Bailard's Lyell Immunopharma position peaked at $187K in Q4 2021.
79 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2022.

Based on Bailard's 13F filing for Q1 2022, filed 25 Apr 2022.